Phase III trial reports that ofatumumab reduces relapses of multiple sclerosis

Written by Alice Bough (Future Science Group)

Researchers based at the University of California San Francisco (UCSF; CA, USA) have completed a Phase III, multicenter clinical trial for the drug ofatumumab. The study aimed to assess the effects of the drug on inflammation, disease progression and relapse rate in relapsing multiple sclerosis (MS). This trial follows on from the ASCLEPIOS I and ASCLEPIOS II trials, sponsored by Novartis (Basel, Switzerland), in which ofatumumab was found to be superior to teriflunomide, a daily pill commonly prescribed for MS. The study, published in The New England Journal of Medicine, recruited over 900 individuals with MS to receive monthly injections...

To view the full article, please register now for access

It's completely free